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Background: The optimal timing of cardiac stem cells administration is still unclear. We assessed the safety of
same-day and delayed (one week) delivery and the possible influence of the timing on the therapeutic outcomes
of allogeneic porcine cardiac stem cells administration after acute myocardial infarction in a closed-chest
ischemia-reperfusion model.
Methods: Female swine surviving 90 min occlusion of the mid left anterior descending coronary artery received an
intracoronary injection of 25x106 porcine cardiac stem cells either two hours (n = 5, D0) or 7 days (n = 6, D7) after
reperfusion. Controls received intracoronary injection of vehicle on day 7 (n = 6, CON). Safety was defined in terms of
absence of major cardiac events, changes to the ECG during injection, post-administration coronary flow assessed using
the TIMI scale and cardiac troponin I determination after the intervention. Cardiac Magnetic Resonance was performed
for morphological and functional assessment prior to infarction, before injection (D7 and CON groups only), at one and
10 weeks. Samples were taken from the infarct and transition areas for pathological examination.
Results: No major adverse cardiac events were seen during injection in any group. Animals receiving the therapy on
the same day of infarction (D0 group) showed mild transient ST changes during injection (n = 4) and, in one case,
slightly compromised coronary flow (TIMI 2). Cardiac function parameters and infarct sizes were not significantly
different between groups, with a trend towards higher ejection fraction in the treated groups. Ventricular volumes
indexed to body surface area increased over time in control animals, and decreased by the end of the study in animals
receiving the therapy, significantly so when comparing End Diastolic Volume between CON and D7 groups (CON:
121.70 ml/m2 ± 26.09 ml/m2, D7: 98.71 ml/m2 ± 8.30 ml/m2, p = 0.037). The treated groups showed less organization of
the collagenous scar, and a significantly (p = 0.019) higher amount of larger, more mature vessels at the infarct border.
Conclusions: The intracoronary injection of 25x106 allogeneic cardiac stem cells is generally safe, both early and 7 days
after experimental infarction, and alleviates myocardial dysfunction, with a greater limitation of left ventricular
remodeling when performed at one week.
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Cardiovascular diseases remain a major cause of death
and disability, with coronary heart disease being respon-
sible for 20 % of all deaths in Europe [1]. Adult stem
cells are emerging as a therapeutic option, with a modest
improvement in cardiac function after cell transplantation
[2, 3]. In recent years, cardiac stem cells (CSCs) have been
proved in numerous preclinical studies to improve left ven-
tricular function and attenuate remodeling after myocardial
infarction [4-12]. Based on these experimental works, hu-
man trials have been initiated. Promising results have been
reported from the use of autologous cardiac cells in the set-
ting of heart failure, either after coronary artery bypass
grafting [13, 14] (SCIPIO trial, NCT00474461) or after cor-
onary stenting [15, 16] (CADUCEUS trial, NCT00893360).
However, the autologous approach presents obvious
drawbacks in that the time needed for cell expansion
conditions the time frame for treatment. Allogeneic cells
emerge as a promising option, and several studies using
this strategy have been reported [7, 17-23]. An allogeneic
approach offers the possibility of administering cells very
early after the ischemic event, as an “off-the-shelf” product
that, at the same time, can be subjected to higher quality
controls than autologous products [24, 25]. The earliest
possible administration has been advocated [2, 24, 26, 27].
Data from clinical trials using bone marrow cells, however,
seem to support a best effect of these cells when adminis-
tered after the 4th day post-infarction [28]. To date, allo-
geneic CSCs have been tested in swine 2-3 weeks [5] and
immediately [22, 23] after infarction. The optimal timing
of CSCs administration is still unclear. The myocardial
substrate immediately after infarction may be detrimentalFig. 1 Study design. n = number of pigs. AMI = acute myocardial infarction
infarction. CMR = cardiac magnetic resonancefor cell engraftment, due to an early rise in reactive oxy-
gen species and inflammatory cytokines. Conversely,
once the inflammatory phase is over, scar formation and
adverse remodeling are under way, and therefore the ef-
fect of the cells may be limited [29], although there are
also studies reporting beneficial effects at subacute and
chronic settings [30, 31].
We undertook this study to assess the safety of early de-
livery and the possible influence of the timing of allogeneic
porcine CSCs (pCSCs) delivery after acute myocardial in-
farction (AMI) on cardiac function in a closed-chest swine
model of reperfused myocardial infarction.
Methods
Experimental protocol
The study protocol was approved by the Institutional
Animal Care and Use Committee, and it complied fully
with the Directive 2010/63/EU of the European Parlia-
ment on the protection of animals used for scientific
purposes.
The study flow chart is presented in Fig. 1. Female
domestic swine weighing 30-35 kg were used for this
study (n = 19). Prior to inclusion in the protocol, all an-
imals underwent a complete physical examination and
serum biochemical analyses. Study animals received
400 mg oral amiodarone from 5 days prior to infarct
induction to 3 days after it, and 500 mg aspirin and 300
mg clopidogrel 24 h before model creation. The anti-
thrombotic medications continued through the study
until euthanasia was performed (500 mg aspirin and 75
mg clopidogrel). All the procedures were performed
under general anaesthesia.. pCSC = porcine cardiac stem cells. TIMI = Thrombolysis in myocardial
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After being fasted for 24 h, animals were premedicated
by the intramuscular injection of ketamine (20 mg/kg).
10 min after premedication, access to an ear’s marginal
vein was obtained and anaesthesia was induced with
intravenous (IV) 1 % propofol (3 mg/kg). Endotracheal
intubation was performed using cuffed endotracheal
tubes (sizes 6.5 -9, depending on the animal’s weight).
For cardiac magnetic resonance (cMR) examinations, an-
aesthetic maintenance was performed with a continuous
propofol infusion (8-12 mg/kg/h). Animals were connected
to a MR-compatible ventilator (TransPAC T200, Smiths
Industries Medical Systems, UK) and mechanical pressure
controlled ventilation was established with a FiO2 of 0.5 to
assure normocapnia.
During infarct induction and pCSCs administration, an-
aesthesia was maintained using a continuous IV infusion
of a combination of 1 % propofol (10-12 mg/kg/h) and
remifentanyl (15-18 μg/kg/h). Endotracheal tubes were
connected to a semi closed circular anaesthetic circuit at-
tached to a ventilator (Leon Plus, Heinen & Löwenstein,
Bad Ems, Germany) with a fresh gas flow rate of 1 L/min
(0.4/0.6 mixture of oxygen and air). Controlled ventilation
was established with a tidal volume of 6-8 mL/kg to obtain
normocapnia (with a CO2 pressure of 35-40 mmHg).
Systemic heparin was injected IV (150 IU/kg) 5 min
prior to percutaneous sheath placement.
Anaesthetic monitoring included cardiovascular and
hemodynamic parameters such as: heart rate, electrocar-
diography, pulse-oxymetry and invasive arterial blood
pressure. Ventilatory parameters registered were: re-
spiratory rate, oxymetry, airways pressure, inspired and
end-tidal CO2 concentration.
Once the follow-up was completed, animals were
euthanized by a lethal dose of potassium chloride (1-2
mmol/kg) while under deep anaesthesia, as recom-
mended by the American Veterinary Medical Associ-
ation (AVMA Guidelines for the Euthanasia of Animals:
2013 Edition. Available at: https://www.avma.org/kb/
policies/documents/euthanasia.pdf ).
Infarct induction protocol
For infarct creation, animals were fixed at the table in the
dorsal decubitus with caudal extension of the hind limbs,
and the groin area was prepared for access. Under sterile
conditions, a right femoral arterial access was established
using the Seldinger technique and a 7 Fr introducer sheath
(Terumo, Inc. Tokyo, Japan) was placed percutaneously
into the femoral artery. Under fluoroscopic guidance
(Philips Mobile Digital Angiographic System-BV Pulsera,
Philips Medical Systems, Best, The Netherlands) a 6 Fr
hockey stick guiding catheter (Mach 1 ®, Boston Scientific
Corporation, Natick, MA, USA) was introduced and
placed at the origin of the left coronary artery. 150mg ofIV amiodarone in 5 % glucose saline were administered
slowly prior to left anterior descending coronary artery
(LAD) engagement with the guiding catheter. As soon as
the guiding catheter was placed at the origin of the left
coronary artery, 150 μg of nitroglycerin were administered
through it to prevent coronary spasm. Coronary angio-
grams were then obtained in the 40° left anterior oblique
(LAO) projection to better demonstrate the length of the
LAD, and a 0.014” guidewire (Hi-torque. Abbott Vascular,
Santa Clara, CA, USA) was advanced inside the LAD.
After measuring the diameter of the LAD immediately
below the origin of the first diagonal branch, a coronary
bare metal stent (Apolo. Iberhospitex SA, Barcelona,
Spain) of appropriate diameter was advanced to this loca-
tion. Before occluding the artery, a bolus of 2 % lidocaine
(1mg/kg) was administered and the balloon was then
inflated. Correct occlusion was assessed by contrast injec-
tion through the guiding catheter immediately after bal-
loon inflation and before deflation. The occlusion was
maintained for 90 min. In the event of the animals develop-
ing ventricular fibrillation during the occlusion, manual
chest compressions and 200 J biphasic defibrillation shocks
(Zoll M series biphasic 200J, Zoll Medical Corporation,
Massachusetts, USA), and pharmacological therapy when
needed were used to revert them. After balloon deflation
and removal, a post procedural coronary angiogram was
obtained to assess coronary patency and flow, which was
scored following the Thrombolysis In Myocardial Infarction
(TIMI) grade flow. Animals were kept under anaesthesia
with lidocaine infusion for another hour, and were then re-
covered and sent back to the animal housing facility for
postoperative observation. Subjects allocated to injection
on day 0 were kept under close supervision and lidocaine
infusion for another hour, before performing the pCSCs
injection as described below. In all cases, postoperative an-
algesia was obtained with 10 μg/kg/12h of IM buprenor-
phine during the first 24h. A fentanyl transdermic release
patch (25 μg/h) was used to assure correct analgesia in the
immediate postoperative period. Prophylactic antibiotics
were administered in all cases for 5 days after infarct induc-
tion (ceftiofur hydrochloride).
pCSCs preparation
Porcine CSCs were obtained from male Large White pigs.
After mechanical and enzymatic digestion of heart tissue
samples, a cellular suspension was obtained and CD45
positive cells immunodepleted. CSCs were immunose-
lected from cell suspension using anti cKit antibodies. Iso-
lated cells were seeded in a culture plate and in vitro
expanded using culture medium with 10 % Foetal Bovine
Serum (FBS) and growth factors to obtain a Working Cell
Bank (WCB). Cells at WCB were frozen in DMEM
medium with 10 % of pig serum and 10 % of DMSO at
10x106 cells /ml and stored in a liquid nitrogen tank. The
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quantitative PCR (qPCR) and ELISA. For cell administra-
tion, vials were thawed in a 37°C bath and the cell suspen-
sion mixed with 25 ml of saline buffer with 5 % of bovine
serum albumin. Cells were centrifuged and the super-
natant removed. The cell pellet was resuspended in phos-
phate saline buffer (PBS) with 5 % of BSA (bovine serum
albumin) and passed through a 40 μm cell strainer. Cell
concentration and viability was tested using trypan blue
exclusion and cell concentration adjusted at 2.1x106 cell
/mL for administration using PBS-5 % BSA.
Group allocation and pCSCs administration
Surviving animals were sequentially allocated to the con-
trol group (CON, n = 6), pCSCs injection on day 0 (D0,
n = 5) or pCSC injection on day 7 (D7, n = 6).
In the D0 group, the administration was performed 2
h after reperfusion, to allow for stabilization of the ani-
mal. In the CON and D7 groups, administration was
performed 7 days after infarct induction, immediately
after acquiring a cMR study. Access to the LAD was
established using the same protocol described for infarct
creation, and a 21 Fr microcatheter (Microferret infusion
catheter, Cook Medical. Bloomington, IN, USA) was
placed at the level of the coronary stent. The total vol-
ume to be administered was divided in two 6mL syrin-
ges, and administered in two injection cycles separated
by a 3 min rest period. Each half dose was injected
manually over 3 min. Once the stated volume was in-
fused, we waited for 5 min before obtaining a coronary
angiogram to assess coronary TIMI grade flow again.
The femoral sheath was then removed and haemostasia
of the puncture site achieved by manual compression.
Blood samples were taken for cardiac troponin I
(cTpnI) assay before infarction and 24h after reperfusion
(all groups) and also before and 24h after pCSCs/vehicle
administration (CON and D7 groups) (AQT90 Flex,
Radiometer Iberica SL, Madrid, Spain).
MR examinations
Cardiac Magnetic Resonance studies were performed for
morphological and functional assessment before injec-
tion (CON and D7 groups), one and 10 weeks after
pCSCs/vehicle infusion.
In all cases, animals were placed inside the MR sys-
tem (Intera 1.5 T, Philips Medical Systems. Best, The
Netherlands) in the sternal decubitus. Retrospective
cardiac triggering was used. A 4 elements phase array
coil was placed around the animals’ chest. Images were
acquired in the intrinsic cardiac planes: short axis, ver-
tical long axis and horizontal long axis views. For meas-
urement of left ventricular function and mass breath
hold gradient echo cine images were obtained over the
entire left ventricle (LV). Typical parameters used were:slice thickness: 8 mm, no gap, Field of view (FOV): 320
x 320 x 80, matrix: 192x192, flip angle: 60°, repetition
time/echo time (TR/TE): 4.4/2.2. For infarct size mea-
surements, short axis images were acquired 5 to 15 min
after the injection of 0.2 mmol/kg of a gadolinium-
based contrast agent (Gadobutrol. Gadovist 1.1 mmol/l,
Bayer Schering Pharma AG, Berlin, Germany) using a
breath-hold 3D gradient-echo inversion-recovery se-
quence. Inversion time was chosen for each sequence
using a Look-Locker sequence and selecting the time
that yielded the best nulling of the myocardial signal,
which typically ranged from 150 to 190 ms. Imaging pa-
rameters used for the delayed enhancement images were
slice thickness: 8 mm, no gap, FOV: 330 x 330 x 50,
matrix: 224x200, flip angle: 15°, TR/TE: 4.9/1.67. MR im-
ages were analyzed by a researcher blinded to the group
allocation using a commercially available software
(Extended MR WorkSpace 2.6.3.2. Philips Medical
Systems. Best. The Netherlands.). For these analyses,
endocardial and epicardial borders were manually delin-
eated in end diastolic and end systolic short axis views, in
all slices, and the following LV functional parameters were
calculated: end diastolic volume (EDV), end systolic vol-
ume (ESV) and ejection fraction (EF). The thickness of the
infarcted (septum) and healthy lateral free wall were also
measured in end diastolic short axis views. Similarly,
infarct size calculations were performed in the delayed en-
hancement images by manually defining the normal and
infarcted myocardium with computer assistance to obtain
the percentage of infarcted left ventricle. Central dark
zones within the area of hyperenhancement were in-
cluded. All determinations were performed by an investi-
gator blinded to the group allocation.
In order to perform a robust comparison and avoid
the influence of the animal’s growth on the results, vol-
ume data were indexed by Body Surface Area (BSA),
using the weight-based formula described by Kelley [32].
End of study and post-mortem examinations
Animals were euthanized 10 weeks after infarction. On
the allotted euthanasia day, immediately after the corre-
sponding cMR study, a coronary angiogram was obtained
via a percutaneous access to a femoral artery for TIMI
flow grade scoring and euthanasia was performed as de-
scribed above. Prior to hearts explantation, pericardial
fluid (PF) samples were collected for TNF-alpha and active
TGF-beta levels quantification. Cytokines were measured
using quantitative ELISA kits for porcine TNF-alpha
(R&D systems) and active TGF-beta (BioLoegend, San
Diego, CA). PFs were centrifuged for 5 min at 450 x g,
passed through a 0.22 μm filter and frozen at -20°C until
assayed. PFs were thawed at room temperature and ELISA
was performed according to manufacturer´s instructions.
ELISA plates were read at 450 nm using the ELISA Reader
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grams of cytokine per ml of PF. Explanted hearts were
photographed to document macroscopic infarct distribu-
tion, cut into serial slices and placed in a 1 % solution of
2,5,3-triphenyl tetrazolium chloride (TTC) in phosphate
buffer at 37°C for 10 min.
Samples were taken from the infarct and transition areas
for pathological examination, embedded in paraffin, sliced
into 5 μm thick sections and stained with haematoxylin-
eosin and Masson’s trichromic. As previously described
[21], the density and size of blood vessels present at the in-
farct border was determined from five randomly chosen
areas of each sample. A scoring system comprising from 0
(absent or normal) to 4 (severe) was used to score the
presence of inflammatory infiltrate, fibrosis, necrosis, cal-
cification or teratoma formation.
For the detection of male-derived pCSCs in female
hearts, Y-chromosome PCR was carried out from tissue
samples obtained from the transition area in all hearts.
DNA extraction was performed with TRI Reagent (Sigma,
St. Louis, MO, USA) according to the manufacturer's in-
structions. The detection of male cells in a female recipient
was carried out by PCR using the Taq DNA Polymerase
(Invitrogen, Carlsbad, Ca). Amplification consisted in 40 cy-
cles of 30 s at 94°C for melting, 30 s at 55°C for annealing
and one min at 72°C for amplification. The primers 5´-AC
AGAGGGCCTATTCATCTCAG-3´ (forward) and 5´-CTT
AATGGCTAATCACGGGAAC-3´ (reverse) were designed
to allow the amplification of Y-chromosome specific se-
quences (NCBI Reference Sequence: NC_010462.2).
Statistical analysis
Data are presented as means ± standard deviations. Data
were checked for normality using the Shapiro Wilks test.
Differences between groups were identified and com-
pared using the Kruskal-Wallis and Mann-Whitney U
tests. Values of p < 0.05 were considered significant. Cal-
culations were performed using the SPSS 18.0 statistical
package for Windows (SPSS Inc, Chicago, Ill).
Results
A total of 19 female pigs were used for this study. One
of the animals died during infarct induction, before
group allocation, and a second animal belonging to D0
died during the stabilizing period, prior to pCSCs ad-
ministration. Infarction was successfully induced in all
surviving animals, as demonstrated by an increase in
Troponin I values to over our system detection limit
(>25 μg/L) in all animals 24 h after model creation. No
further animal deaths, of cardiac or any other origin,
were seen in this study.
As indicated above, pig CSCs were phenotypically
characterized by flow cytometry, qPCR and ELISA. Pig
cells were positive for CD29, CD44, CD90, CD105, andGATA4 and negative for CD45 (Fig. 2) and secrete IGF-
1, TGF-β and CCL2 factors. In addition, isolated pig
cells had clonogenic capabilities and were able to differ-
entiate in vitro to smooth muscle, endothelial cells and
cardiomyocytes (see Additional files 1 and 2). The pheno-
typical characterization indicated that in vitro expanded
porcine cells were equivalent to previously described hu-
man CSCs [33]. Post-thaw viability of cryopreserved
pCSCs was >95 % and no aggregates were present.
Injection was successful in all animals at both 0 and 7
days after AMI, in absence of major adverse cardiac
events (MACEs). Slight ST-segment elevations were seen
in 4 animals from D0 during the injection procedure,
but the ST wave spontaneously returned to pre-injection
values once the administration was completed in all
cases. No changes in the ECG were seen during pCSCs/
vehicle administration in any CON or D7 animal.
Post injection coronary flow was scored as TIMI 3 in all
animals but one belonging to the D0 group, in which TIMI
2 flow was demonstrated after pCSCs administration.
A slight increase in Troponin I levels was seen in D7
and CON 24 h after therapy administration (Table 1),
but this increase was not significantly different between
groups (Mann Whitney U-test, p = 0.46). Troponin I in
D0 animals was elevated beyond the higher detection
limit of the laboratory, (>25 μg/L). However, in these
animals, this time point represented also the 24 h after
infarction measurement.
CMR-derived cardiac function data are presented in
Table 2 and Fig. 3. No differences were seen between
groups in baseline functional data. Intergroup compari-
sons revealed no significant differences in EF or infarct
sizes at any time point between study groups. Indexed
ventricular volumes after 10 weeks were greater in the
control group, but this difference only reached statistical
significance in EDVi between CON and D7 on week 10
(p = 0.037, Mann Whitney U test). The evolution of these
parameters within each group over time is shown in Fig. 3.
In absence of significant differences, EF increased slightly
in both treated groups, while in the control group it
remained stable. Similarly, EDVi decreased in D7 from 1
week after injection to the end of the study (N.S), while it
increased slightly in D0 animals. ESVi, however, decreased
over time in both treated groups. A clear trends towards
increased indexed volumes was seen in CON animals
(EDVi was 98.71mL/m2 ± 8.3mL/m2, 106.04mL/m2 ±
7.26mL/m2 and 121.70mL/m2 ± 26.09mL/m2 and ESVi
was 53.45mL/m2 ± 8.01mL/m2, 61.18mL/m2 ± 12.08mL/
m2 and 72.72mL/m2 ± 27.18mL/m2, respectively in D7, D0
and CON). Septal thickness showed a trend towards a
greater thinning in the CON group, followed byD7 and
D0 animals, while free LV lateral wall thickness increased
slightly in all cases, in absence of significant intergroup
differences (Table 3).
Fig. 2 Porcine CSCs characterization. a Morphology of porcine CSCs in a primary cell culture. b Porcine CSCs are able to proliferate in non-adherent
conditions forming cardiospheres after 7 days in suspension. c Cell surface expression analysis by flow cytometry. Expression of CD90, CD44, CD29,
CD105 and CD45 is shown (empty histogram) and the number of positive cells is indicated (%). Grey filled area represents isotype control
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terior, anteroseptal and apical septal left ventricle was vi-
sualized on the follow up cMR examinations. The size of
the infarct, measured in percentage, decreased over time
in all groups (Table 2, Fig. 3).
TNF-alpha and active TGF-beta levels were quantified
by ELISA in PF collected upon euthanasia. As shown inTable 1 Cardiac Tpn values (μg/l) measured during the study
GROUP Baseline (pre infarction) 24 hours post-infar
CON 0.060 ± 0.052 >25
D7 0.022 ± 0.024 >25
D0 0.049 ± 0.058 >25
Data presented as mean ± standard deviationFig. 4, TNF-alpha levels were significantly lower in the
groups of animals where pCSCs were injected 2 h after
infarction, compared to not injected animals. However,
there were not significant differences between control
and animals injected one week after the infarction
(Fig. 4A). On the other hand, the levels of active TGF-
beta in PF significantly decreased when pCSCs werection 1 week post-infarction 24 hours post-cells
0.034 ± 0.029 0.327 ± 0.275
0.021 ± 0.009 0.542 ± 0.985
n/a >25
Table 2 Cardiac parameters calculated from Magnetic Resonance exams performed through the study









1 week 10 weeks Baseline
(preinfarction)
1 week 10 weeks
Weight (kg) 32.5 ± 1.87 33.8 ± 1.33 33.0 ± 1.67 39.17 ± 2.71 30.67 ± 1.97 31.00 ± 3.80 30.33 ± 2.73 41.33 ± 5.01 31.60 ± 2.07 34.60 ± 1.67 42.60 ± 4.98
EF (%) 51.57 ± 7.48 38.22 ± 10.4 41.03 ± 5.66 41.70 ± 10.88 51.08 ± 7.68 41.07 ± 7.50 42.17 ± 5.70 45.93 ± 6.15 54.24 ± 8.63 36.58 ± 8.97 42.58 ± 8.80
EDVi (mL/m2) 82.61 ± 18.36 106.24 ± 10.96 110.16 ± 11.49 121.70 ± 26.09* 79.18 ± 13.20 97.86 ± 13.00 106.57 ± 8.42 98.71 ± 8.30* 79.95 ± 7.59 101.65 ± 22.02 106.04 ± 7.26
ESVi (mL/m2) 39.97 ± 9.47 66.1 ± 15.74 65.09 ± 10.39 72.72 ± 27.18 38.92 ± 9.65 57.60 ± 9.85 61.64 ± 8.00 53.45 ± 8.01 36.94 ± 9.58 65.28 ± 19.55 61.18 ± 12.08
% Infarct n/a 17.20 ± 5.54 11.33 ± 2.94 7.50 ± 2.07 n/a 16.33 ± 3.61 13.33 ± 4.88 10.00 ± 4.29 n/a 17.00 ± 3.46 9.40 ± 2.79
Infarct mass (g) n/a 13.28 ± 4.96 7.46 ± 1.92 5.25 ± 1.32 n/a 10.49 ± 2.65 7.95 ± 2.36 6.20 ± 2.45 n/a 12.16 ± 3.88 7.03 ± 2.29
Data presented as mean ± standard deviation. EF: Ejection fraction. EDVi: End diastolic volume indexed to body surface area. ESVi: End systolic volume indexed to body surface area. n/a: Not applicable. * P < 0.05
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control group (Fig. 4B).
Upon euthanasia, anteroseptal transmural fibrous scars of
varied extension were seen in all hearts, with a certain de-
gree of thinning of the left ventricular wall evident in all
cases. However, thinning was greater in animals
belonging to the CON group, which, on TTC staining, ex-
hibited a clear area of non viable myocardium. In the
treated groups, thinning was less, and there was some vi-
able tissue surrounding and infiltrating the scars (Fig. 5).
On light microscopy, these scars were fibrotic with differ-
ent degrees of organization and some scattered inflamma-
tory infiltrate. Histopathological findings are summarized in
Table 4. CON samples exhibited the highest degree of
dense fibrosis (severe), with almost complete replacement
of myocardiocytes by a mature fibrotic scar, while the
treated groups showed less organization of the collagen
content (considered moderate in D0 and slight in D7), in-
terspersed with variably sized clusters of viable myocardio-
cytes. Overall, there were no major differences between
groups in terms of inflammation (mild to moderate),Fig. 3 Changes over time in cardiac function parameters. Cardiac function wa
ventricular ejection fraction. EDVi = Indexed end diastolic volume. ESVi = Index
the evolution of these parameters in individual animals over time. d: Changes
(p < 0.05). E: Cardiac MR images obtained at 10 weeks after infarct induction i
injection of 25x106 pCSCs either two hours (D0) or 7 days (D7) after reperfusiopresence of necrosis or calcification (mostly absent, except
in one animal belonging to CON and one belonging to
D0). No evidence of teratoma formation was seen in any
case. No differences between groups were seen in the total
amount of vessels. However, regarding the sizes of these
vessels, Differences were seen between groups using the
non parametric Kruskal Wallis test (p = 0.019). Post-hoc
comparisons showed that the treated groups had a higher
amount of mid and large caliber (and therefore more ma-
ture) vessels compared to CON, significantly so in the case
of D0 (p = 0.008) (Fig. 5).
In order to determine the detection limit of the tech-
nique for Y chromosome detection into the female recip-
ients, preliminary experiments were performed. Samples
with 101, 102, 103, 104 and 105 male cells were mixed to-
gether with one million female cells and amplified by
PCR. This technique showed a detection limit of 100-
1000 male cells per 106 female cells (Fig. 6A). For the
detection of transferred cells, the DNA from different
tissues was isolated and Y chromosome amplified by
PCR. However, as shown in Fig. 6B, male pCSCs weres measured with cardiac magnetic resonance imaging. EF = Left
ed end systolic volume. DE = delayed enhancement. Panels a to c show
between groups. * Denotes statistical significance compared to CON
n animals receiving intracoronary vehicle injection on day 7 (CON), or
n
Table 3 Left ventricular wall thickness (mm) over time
Baseline (preinfarction) Day 0 preinjection 1 week 10 weeks
Septum Lateral wall Septum Lateral wall Septum Lateral wall Septum Lateral wall
CON 7.68 ± 1.25 7.28 ± 0.59 6.86 ± 1.81 7.85 ± 0.40 5.24 ± 2.23 8.08 ± 1.67 2.98 ± 0.28 7.97 ± 0.73
D7 6.18 ± 1.08 6.68 ± 1.13 6.40 ± 1.07 7.41 ± 0.76 4.79 ± 1.30 7.21 ± 0.64 3.69 ± 0.76 7.68 ± 0.41
D0 6.82 ± 0.76 6.99 ± 0.67 n/a n/a 7.22 ± 0.93 6.94 ± 0.60 4.66 ± 1.61 8.56 ± 0.76
Data presented as mean ± standard deviation
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administration.
Discussion
The beneficial effect of CSC administration in the setting
of myocardial infarction has been demonstrated in nu-
merous preclinical studies [5-8, 10-12] and preliminary
clinical data [13-16] have reported unprecedented good
results using heart derived cellular products. SCIPIO in-
vestigators reported a 12.3 % increase in LVEF at one
year [13], whereas the patients enrolled in the CADU-
CEUS trial did not show any changes in this parameter
compared to the control group after one year, despite
demonstrating a 11.1 % reduction in scar size (compared
to unchanged scar size in control patients) and an in-
crease in viable myocardium by 22.6g in treated patients
versus 1.8g in controls [15]. In the present study, we
focus on the timing of allogeneic CSCs administration
via the intracoronary route in a closed-chest model of
MI. While some results with heart derived products ad-
ministered immediately after experimental infarction
have been reported in abstract form [22, 23], to the best
of our knowledge, no comparative timing study using
CSCs has been performed. Our findings following the
intracoronary injection of 25x106 confirm the safety of
this approach, both early and 7 days after experimental
AMI, with no MACEs during administration or laterFig. 4 Cytokines levels in pericardial fluid. Cytokines levels were measured
TNF-alpha and active TGF-beta. Absorbance was read at 450 nm and cytok
curve. The graphs represent mean values ± standard deviation of four inde
TGF-beta (b) determinations. The results were analyzed through a Student’s
ure with the control group (*p < .05)cardiac deaths seen in any animal. In terms of efficacy,
our functional results suggest a better performance of
the pCSCs when administered one week after the ische-
mic insult, while pathological examination points to en-
hanced angiogenesis at both time points, especially so in
the animals receiving pCSCs early after infarction.
The use of clinically compatible methods and techniques
ensures comparability with other works and a rapid trans-
lation of preclinical studies [3]. In this study we not only
used a widely accepted animal model of MI, such as the
closed chest reperfused balloon occlusion porcine model,
but also clinically compatible methods for cell infusion
and to study the evolution of heart function. Swine
present many similarities to the human heart and there is
an increasing amount of preclinical works performed in
pigs available for comparison, that can help interpreting
and putting the results in context [3].
Intracoronary administration is, from a clinical point
of view, the most practical method for cell delivery to
the heart, as it is widely available worldwide, less inva-
sive than other administration routes and the cells can
be administered to the entire myocardium at risk [4, 10].
Concerns have been raised, however, regarding the safety
of this approach, as several studies using cells from other
[19, 24, 34] and cardiac [6] origin have reported in-
stances of no reflow phenomena or increased troponin,
thus dictating a limitation on the dose [34], the use ofin the filtered pericardial fluid using quantitative ELISA kits for porcine
ines levels (expressed in pg/ml) were extrapolated from a calibration
pendently performed experiments (n = 4) for TNF-alpha (a) and active
t-test for variables with parametric distribution, comparing each meas-
Fig. 5 Typical histological and macroscopical appearance of the infarcts. Panels a through c: TTC staining shows the extension of infarcted tissue
in the different groups. Panels d through F Massons trichromic evidences increased collagen in the control animals, while some medium to large
size vessels can be seen in treated animals (arrows). The bar represents 500 μm. G. Distribution of vessels’ sizes as determined at the infarct
border. * denotes statistical significance (p < 0.05)
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less, there are many reports using this route in absence
of complications for different cell types [5, 10, 13, 14, 20,
35]. To ensure the safety of our approach, we performed
a pilot study with intracoronary injection of pCSCs in
healthy swine, and we did not find any evidence of
microinfarction or cardiac toxicity by either cMR or
pathological assessment [36]. As previously reported [10,24], the size of the cells used in this study, which ranged
between 12-13 μm, may confer a clear advantage for
their intracoronary administration over other stem cells
currently in use.
In spite of its accuracy and reproducibility making it
the preferred modality for inter-study comparisons [3],
cardiac MR is not frequently used in preclinical studies
[34]. Considering that cell therapy may cause changes in
Table 4 Summary of histopathological findings
CON (n = 6) D7 (n = 6) D0 (n = 5)
Inflammatory infiltrate 1.5 1 2
Fibrosis 4 1 3
Necrosis 2 1 2
Calcification 0 0 0
Teratoma 0 0 0
Data presented as median scores. 0: Absent, 1: slight, 2: mild, 3 moderate and
4: severe
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creased extravasation of contrast), Malliaras et al. recently
studied the kinetics of gadolinium within the infarcted
swine heart with or without cell therapy, finding no differ-
ences between groups and thus confirming the usefulness
of this technique for monitoring regenerative efficacy [5].
In order to be able to test the administration of the ther-
apy immediately upon reperfusion, we have used allogeneic
cells, as previously performed by others using cardiac-
derived cell products [5, 7, 11, 22, 23]. The advantages of
using allogeneic cells have recently been highlighted by dif-
ferent groups [25, 30, 37, 38]. Most of the work performed
with allogeneic cells in the heart has used MSCs. Clinic-
ally, the POSEIDON study, while not powered to show
efficacy, reported similar safety profiles between allo-
geneic and autologous cell sources [30]. Preclinically, a
recent meta-analysis including 82 papers dealing with
large animal studies of cell therapy in ischemic heartFig. 6 Y chromosome detection of intracoronary delivered pCSCs. a In ord
male donor were mixed with 106 pCSCs from a female donor at the indica
amplification using Y chromosome specific primers. PCR allowed the detec
cells. b Female pigs were intracoronary injected with male-derived pCSCs.
A representative PCR for each group is shown. As negative and positive co
were amplifieddisease showed that both cell types yielded similar increases
in LVEF and decreases in EDV compared to placebo [38].
Since only one of those studies dealing with allogeneic cells
included in the meta-analysis used immunosuppression,
the authors support that allogeneic cell therapy can be per-
formed without immunosuppression with positive results
on functional cardiac parameters. Accordingly, we used no
immunosuppressive therapy in this study, an approach that
has been proved safe in other works [5, 7, 30, 38, 39], and
that may open the door to a real off-the-shelf treatment op-
tion for cardiac diseases [37].
Nonetheless, and looking towards clinical translation,
the allogeneic rejection risk of CSCs equivalent to those
we have used has been recently described. In this paper,
the authors demonstrated that hCSCs shift their signaling
capacities within the allogeneic setting towards signals that
promote the development, maintenance, and functioning
of anti-inflammatory response [33]. Moreover, a thorough
characterization of the immunologic properties of cardiac
derived stem cells for allogeneic use has been performed
[7]. In that study, the baseline immunophenotype of the
cells supported an allogeneic use: CDCs were found to ex-
press MHC class I antigens, which confer protection
against natural killer cell-mediated deletion, while no
MHC class II antigens were identified, allowing the cells
to escape direct recognition from CD4+ T helper cells.
In this paper, we also aimed to compare the TNF-alpha
and TGF-beta levels between different study groups. Al-
though other authors have determined these cytokines iner to determine the sensitivity of PCR amplification, pCSCs from a
ted ratios. Genomic DNA was extracted and subjected to PCR
tion of male cells with a sensitivity of 100-1000 cells per 106 female
After euthanasia, heart tissue samples were collected for PCR analysis.
ntrols, the genomic DNA from female and male pCSCs cells
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pericardial fluid at 10 weeks post-infarction. We consider
that the measurements of these cytokines in the pericar-
dial fluid may better reflect the immune status in the
infarcted hearts. The first cytokine we measured was
TNF-alpha which is produced (at least in part) by the
myocardium [41] and has been extensively described in
different animal models of cardiovascular failure [42]. As
expected, our measurements in the pericardial fluid
showed high levels of TNF-alpha in the CON group
(infarcted animals without cells). This result is in agree-
ment with a previous report using rats as animal models
of acute myocardial infarction [43] and clinical data from
infarcted patients [44]. In these papers, rats and humans
showed higher levels of TNF-alpha after long-term follow-
up. The relevance of our results lies in the significant de-
crease of TNF-alpha observed in those infarcted animals
which received an intracoronary administration of cardiac
stem cells. Our results appear to be different from prior
reports [40], where TNF-alpha levels were similar follow-
ing cellular transplantation. However, there are several dif-
ferences between the experimental procedures that could
account for this difference in results: Firstly, we measured
cytokines in PF rather than in serum. Secondly, the ad-
ministered stem cells are different (bone marrow-derived
stem cells in Schuleri´s report and cardiac stem cells in
our work). And thirdly, the administration routes are also
different (epicardial versus intracoronary administration).
These differences may suggest that, either intracoronary
administration and/or the cardiac stem cells may favor the
decrease of TNF-alpha levels.
Regarding TGF-beta, our study has been only focused
in the quantification of active TGF-beta in the pericar-
dial fluid. Similarly to other studies, our results demon-
strated higher levels of this cytokine in the pericardial
fluid of untreated infarcted animals [45]. Surprisingly,
TGF-beta was significantly lower in those infarcted which
received an intracoronary administration of cardiac stem
cells, either immediately or 7 days after infarction. These
results are difficult to interpret because of the pleiotropic
role of TGF-beta [46]. However, as TGF-beta levels were
quantified in the active form, here we hypothesize that
some of the TGF-beta activators (MMP-2, MMP-9,
Thrombospondin-1, reactive oxygen species, acidic envir-
onment and others) could be down modulated in those
animals which received the intracoronary administration
of cardiac stem cells. Although this hypothesis should
be further demonstrated, previous reports have demon-
strated that intracoronary administration of adult stem
cells induces the downregulation of metalloproteinases
in myocardium (MMP2 and MMP9) after myocardial
infarct [47].
Finally, it is important to note that, the analysis of only
two cytokines would never provide an accurate descriptionof immunological status after myocardial infarction. In-
deed, a deeper analysis may include a wider range of cyto-
kines, chemokines and growth factors. In any case,
according to our modest and reduced analysis and taking
into account the abundant literature demonstrating the
immunomodulatory properties of these cells, we consider
that intracoronary administration of pCSCs may pro-
vide an anti-inflammatory environment after myocar-
dial infarction. However, 10 weeks post-administration
pCSCs were not detected in any of the samples. We
hypothesize that the anti-inflammatory environment
could be mediated by the paracrine stimulation of en-
dogenous regenerative mechanisms which include the
recruitment and expansion of endogenous stem cells
with strong immunomodulatory properties [48], al-
though this hypothesis was not tested in our study.
Cellular therapy may work via the de novo formation
of myocytes and vascular structures, the activation and
growth of resident progenitor cells via a paracrine effect
mediated by the implanted cells, or a protective effect of
the cells (and their released factors) on the myocardium
at risk [49]. These three mechanisms are not mutually
exclusive, and different groups have published evidences
of all three [4, 12, 26, 39]. The relative roles of these dif-
ferent mechanisms of action in cardiac derived cell
products have been studied in immunocompromised
mice receiving Cardiosphere-derived cells (CDCs) [50].
This group injected human CDCs in the peri-infarct area
of SCID mice after permanent coronary ligation, in
order to assess the direct and paracrine contributions of
cardiac derived cell therapy to the regeneration obtained
after administration in an infarcted heart and quantify
the relative contributions of each mechanism to the
beneficial effects observed after therapy. Since they use
human cells in a mice model, they were able to track the
paracrine factors secreted by human cells at one and
three weeks after cell administration, as well as identify
cells of human origin newly integrated into the cardiac
capillaries and muscles. On the one hand, no original
(luciferase labelled) CDCs could be detected at three weeks.
On the other hand, and despite an overall doubling of capil-
lary density, only 9.6 ± 2.7 % of the total capillaries were of
human origin, and in the muscular component, only 11.8 ±
4.5 of detected myosin heavy chain was human in origin.
They conclude that the major contributors to the mechan-
ism of regeneration are paracrine effects, exerted both on
the myocytes and on endogenous stem cells.
We therefore hypothesize that the administration of
pCSCs in our model puts in motion a paracrine system
that activates survival pathways on the cells at risk and
activates the endogenous stem cell compartment [48].
Once these events are triggered, the presence of the cells
is not needed to maintain the benefit, as demonstrated
in prior studies with heart derived products, where no
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past the administration [11, 50, 51]. Similarly, we did not
find any evidence of Y-chromosome in samples from our
female hearts transplanted with male pCSCs 10 weeks
after administration. However, allogeneic transplantations
have been reported to exert sustained beneficial effects on
infarcted hearts’ structure and function that persist over
time, up to 6 months post treatment [7]. This short term
permanence of the cells in the myocardium and the appar-
ent long term benefit conferred regardless of it is another
argument in favour of the absence of immunosuppressive
therapy.
The timing of cell delivery may be critical, and there
are arguments for both early and deferred administration
in the setting of acute myocardial infarction. The opti-
mal time is probably defined by the equilibrium between
the positive and negative influence of the various cyto-
kines present at the myocardium at this time [29]. Most
experimental studies administer the therapy either im-
mediately or at around one week after MI [3]. Those
groups advocating the earliest possible administration of
the cells after infarction [2, 4, 26, 27] support this ap-
proach based on the experimental data documenting a
beneficial effect on the cells at risk by the paracrine ac-
tion of the exogenous cells. Moreover, the administration
of IGF-1 and HGF directly into the infarct related artery
in experimental infarctions in swine improved cardio-
myocyte survival, decreased collagen deposition and en-
hanced angiogenesis at 60 days after AMI, thus resulting
in decreased scar formation and improved ventricular
function [4]. Immediately after reperfusion, the inflam-
matory cardiac milieu may adversely affect the cells
function and survival. In order to be able to exert a
beneficial influence, the cells first need to survive the
acute stage. There have been different ways to address
this, such as the promotion of cell survival, for example
by the concurrent administration of simvastatin [52] or
by activation of Akt, a serine-threonine kinase [18], or
by the transplantation of high doses of cells. Richardson
et al reported a recent study comparing early and late
administration of two doses of MSCs in infarcted rats,
describing that, while all four groups receiving MSCs ex-
hibited some improvement compared to control animals,
this improvement was greater in the early high dose
(2x106) and lower in the early low dose (106) administra-
tion group, while no difference between cell doses was
seen on animals receiving MSCs at one week [17].
Other authors prefer to defer the administration until
after this detrimental inflammatory microenvironment
has subsided, to avoid the widespread death of the trans-
planted cells. Clinically, a benefit has been observed
when BMCs are administered 5 days or later after reper-
fusion, with no effect of the cells when infused within 4
days of the ischemic event [28]. A recent meta-analysisof large animal studies showed a trend towards better re-
sults when cells injection was performed over 1 week
after infarction [3].
In our case, there were benefits at both time points,
but the apparent advantages of delayed administration
both in terms of safety profile and of limitation of car-
diac remodeling point to delayed administration being
more effective. Despite being the most widely used par-
ameter to gauge cardiac function, ejection fraction can
be influenced by several confounding variables, and is
highly dependent on afterload and preload, as well as
cardiac rhythm, rate and ventricular shape [16]. On the
other hand, left ventricular dilation after infarction has
been considered the major identifiable risk factor for sub-
sequent cardiac death [53]. ESV, in particular, was de-
scribed in White’s classical work as the major determinant
of survival after MI. The dilatation of the ventricular cavity
can be attributed, among numerous other factors, to in-
farct expansion and ventricular wall thinning secondary to
the scar formation and the replacement of viable, con-
tractile myocytes for stiff collagen fibers, thus increasing
wall stress in a process that ultimately may lead to heart
failure. In this study conducted with a limited sample size
we did not observe significant changes in EF, although the
trend towards EF recovery seen in both treated groups
was absent in the CON group. More promising are the
changes seen in ventricular volumes, as depicted in Fig. 3.
ESVi increased by almost 10 % in the CON animals by
week 10, while both treated groups showed a decrease in
this parameter, (by 8 % in D7 animals and 7 % in D0 ani-
mals), thus pointing to a recovery of systolic function in
the treated groups. In the case of D7, EDVi decreases also
from 1 week after treatment to the end of the study, when
this difference is significant compared to CON (98.71 ±
8.30 mL/m2 in D7 versus 121.70 ± 26.09 mL/m2 in CON).
Neovascularisation, on the other hand, may have been
more advanced in the immediate administration group.
Angiogenesis is considered determinant for improved car-
diac function in response to cell therapy. There was no
increase in the amount of vessels in treated animals com-
pared to controls, but the infarct border in treated animals
presented larger, more mature vessels, more so in the D0
group, suggesting an association of more mature vascular-
isation with the early administration of pCSCs in this ex-
perimental setting. Other studies have reported similar
results, with the amount of vessels being similar between
treated and control animals, but with cell therapy using
MSCs causing an increase in these vessels’ size [21].
Infarct size decreased similarly in all three groups over
time. However, microscopical evaluation of the infarcted
areas revealed the existence of viable myocyte bundles
within the scar in both treated groups, whereas Control an-
imals exhibited a dense collagenous scar, as seen in other
studies [4, 5, 11, 12]. The existence of these interspersed
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of the infarcted wall, and therefore explain the improved
functional results in the treated groups, in absence of differ-
ences in infarct size.Limitations
We recognize that the experimental setting can never be
fully representative of the clinical scenario, as we use
healthy, juvenile pigs without any co-morbidities, while
cardiac patients are generally middle-aged to elderly
people suffering from associated cardiovascular prob-
lems and risk factors, such as hypertension, atheroscler-
osis, and diabetes. Moreover, the animals used in the
present study are still growing. In order to minimize the
influence of weight gain on our interpretation of the re-
sults, as previously reported by others [35], volumes
have been indexed to Body Surface Area. Clinical trials
using CDCs have reported myocardial regeneration, in
the form of increased grams of viable myocardium tissue
over time [15]. Considering the pig’s growth, this kind of
effect could not be assessed in our work. In order to
minimize mortality due to infarct creation, we have ad-
ministered amiodarone prior to model induction, an strat-
egy that has allowed us to greatly decrease mortality in
prior studies [54]. However, it is important to note that, al-
though we consider it unlikely, this may have masked any
arrhythmogenic effects during pCSCs administration
The experimental design defining CSCs administration
on the same day of infarction in group D0 precluded the
acquisition of a baseline (preinjection) CMR in this
group. Since the MR acquisitions need to be gated for
the cardiac cycle, and it is compromised in that prema-
ture ventricular complexes and tachycardia are common
after balloon deflation, the quality of the images that can
be obtained in this setting is poor, and often not of diag-
nostic quality. The first MR study in this group was ob-
tained one week after CSCs administration, and we cannot
know whether at this time point there was any effect of
the cells. For this reason, comparisons between groups
have focused on the 10 weeks time point. This limitation
could have been circumvented by the use of other imaging
techniques that are not so reliant on the cardiac cycle,
such as echocardiography, but this technique in swine is
especially difficult due to the animals’ thoracic wall config-
uration, and thus extremely operator-dependant.
This study was conducted using a small sample size,
which could account for the general lack of statistically
significant differences between groups. However, preclin-
ical trials in large animal models rarely use a high ex-
perimental number [3], probably due to a combination
of economical, logistical and ethical issues. Nonetheless,
we consider that the amelioration of adverse remodeling
in the treated groups supports the beneficial effect of theintracoronary infusion of pCSCs at both early and 7 days
after AMI.Conclusions
In conclusion, the present study suggests that the intracor-
onary administration of allogeneic pCSCs represents a safe
and clinically applicable ancillary therapy that alleviates
myocardial dysfunction, especially when performed one
week after the insult. It may have a timing-related effect,
with early infusion improving angiogenesis, and later infu-
sion having a greater effect on cardiac function as mea-
sured with cMR during this limited follow-up time.
However, and despite the absence of MACEs during injec-
tion or cardiac deaths in any group, safety concerns along
with a greater improvement of cardiac function in this ex-
perimental setting recommend the use of the 1week time
point for the intracoronary injection of allogeneic CSCs.Additional files
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